Table 1.

Activity and response of each treatment in various FR-positive mouse tumor models

AMWL
Tumor modelTreatment regimenPR%CR%Cures%LCK%PTI (d)
KBControls00001.5 ± 2.110
Vintafolide (1 μmol/kg TIW × 2)20001.20.7 ± 0.99–11
PLD (4 mg/kg BIW × 2)2040203.56.6 ± 2.017–24
Vintafolide (1 μmol/kg TIW × 2) + PLD (4 mg/kg BIW × 2)020804.88.2 ± 4.017–19
M109Controls00005.3 ± 5.228–30
Vintafolide (2 μmol/kg TIW × 2)00600.71.0 ± 1.39–14
PLD (4 mg/kg q7d × 3)020602.22.7 ± 2.616–28
Vintafolide (2 μmol/kg TIW × 2) + PLD (4 mg/kg q7d × 3)001003.5 ± 0.916–23
IGROVControls00000.7 ± 1.511
Vintafolide (2 μmol/kg TIW × 2)800201.31.0 ± 1.315
PLD (4 mg/kg BIW × 2)600401.93.8 ± 3.515
Vintafolide (2 μmol/kg TIW × 2) + PLD (4 mg/kg BIW × 2)2020602.03.6 ± 1.015–18
L1210Controls00001.3 ± 1.210
Vintafolide (2 μmol/kg TIW × 2)0000.42.4 ± 1.211–15
PLD (4 mg/kg BIW × 2)0000.31.6 ± 2.010
Vintafolide (2 μmol/kg TIW × 2) + PLD (4 mg/kg BIW × 2)0000.74.0 ± 3.113–22
KBControls00003.0 ± 2.616
PLD (4 mg/kg BIW × 2)80003.94.6 ± 1.415–25
DAVLBH (0.75 μmol/kg TIW × 2)0000.50.2 ± 0.213–15
DAVLBH (0.75 μmol/kg TIW × 2) + PLD (4 mg/kg BIW × 2)0003.48.0 ± 2.927
Vindesine (1 mg/kg TIW × 2)0000.71.4 ± 1.713–15
Vindesine (1 mg/kg TIW × 2) + PLD (4 mg/kg BIW × 2)0002.55.1 ± 3.722–27

NOTE: CR, disappearance of measurable tumor mass (<2 mm3) at some point in the study; cures, CRs without tumor regrowth; PR, volume regression >50% but with measurable (>2 mm3) tumor.